Diflunisal
Approved · EMAAlso known as 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid, Difluorophenylsalicylic acid, Dolobid, 2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid+2 more
2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid, Difluorophenylsalicylic acid, Dolobid, 2-(hydroxy)-5-(2,4-difluorophenyl)benzoic acid, 5-(2,4-difluorophenyl)salicylic acid, Diflunisalum.
Recent clinical, regulatory, research and industry developments relating to this drug.
The Effect of Diflunisal on Familial Amyloidosis
Pilot Study of Diflunisal in HIV-infected Adults
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Attrogy is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Pilot Study of Diflunisal in HIV-infected Adults
The Effect of Diflunisal on Familial Amyloidosis
Recent completions
Trials that read out recently, adding to the completed evidence base.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.